Carboplatin plus paclitaxel combination chemotherapy: Impact of sequence of drug administration on treatment-induced neutropenia

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 118-122

  Markman, Maurie ^a,b   Elson, Paul ^a   Kulp, Barb ^a   Peterson, Gertrude ^a   Zanotti, Kristine ^a   Webster, Kenneth ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatin; Gynecologic malignancies; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 0141534439     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00517-1     Document Type: Article

References (24)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
2. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., Stuart G., Kaye S., Vergote I., Blom R., Grimshaw R., Atkinson R.J., Swenerton K.D., Trope C., Nardi M., Kaern J., Tumolo S., Timmers P., Roy J.-A., Lhoas F., Lindvall B., Bacon M., Birt A., Andersen J.E., Zee B., Paul J., Baron B., Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results . J Natl Cancer Inst. 92:2000;699-708.
3. Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., de Swart C.A.M., Hirsch F.R., Lund B., van Houwelingen H.C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 18:2000;3084-3092.
4. Ozols R.F., Bundy B.N., Fowler J., Clarke-Pearson D., Mannel R., Hartenbach E.M., Baergen R. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC) a Gynecologic Oncology Group trial (GOG 158) . Proc Am Soc Clin Oncol. 18:1999;356a.
5. du Bois A., Lueck H.J., Meier W., Moebus V., Costa S.D., Bauknecht T., Richter B., Warm M., Schroeder W., Olbricht S., Nitz U., Jackisch C. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial . Proc Am Soc Clin Oncol. 18:1999;356a.
6. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., Surwit E.A., Malvlya V.K., Nahhas W.A., Jolles C.J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer . J Clin Oncol. 10:1992;706-717.
7. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., Drouin P., Stanimir R., O'Connell G., MacLean G., Kirk M.E., Canetta R., Koski B., Shelley W., Zee B., Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer a randomized phase III study of the National Cancer Institute of Canada Clinical Trials group . J Clin Oncol. 10:1992;718-726.
8. Connelly E., Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers unexpected incidence of neurotoxicity . Gynecol Oncol. 62:1996;166-168.
9. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies the Cleveland Clinic experience . Semin Oncol. 24:(suppl 15):1997;26-29.
10. Rowinsky E.K., Gilbert M.R., McGuire W.P., Noe D.A., Grochow L.B., Forastiere A.A., Ettinger D.S., Lubejko B.G., Clark B., Sartorius S.E., Cornblath D.R., Hendricks C.B., Donehower R.C. Sequences of Taxol and cisplatin a phase 1 and pharmacologic study . J Clin Oncol. 9:1991;1692-1703.
11. LeBlanc G.A., Sundseth S.S., Weber G.F., Waxman D.J. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res. 52:1992;540-547.
12. de Jonge M.J.A., Loos W.J., Gelderblom H., Planting A.S.T.h, van der Burg M.E.L., Sparreboom A., Brouwer E., van Beurden V., Mantel M.A., Doyle E., Hearn S., Ross G., Verweij J. Phase 1 pharmacologic study of oral topotecan and intravenous cisplatin Sequence-dependent hematologic side effects . J Clin Oncol. 18:2000;2104-2115.
13. Venturini M., Lunardi G., Del Mastro L., Ornella Vannozzi M., Tolino G., Numico G., Viale M., Pastrone I., Angiolini C., Bertelli G., Straneo M., Rosso R., Esposito M. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol. 18:2000;2116-2125.
14. Huizing M.T., Giaccone G., van Warmerdam L.J.C., Rosing H., Bakker P.J.M., Vermorken J.B., Postmus P.E., van Zandwijk N., Koolen M.G.J., ten Bokkel Huinink W.W., van der Vijgh W.J.F., Bierhorst F.J., Lai A., Dalesio O., Pinedo H.M., Veenhof C.H.N., Beijnen J.H. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol. 15:1997;317-329.
15. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D., Gianni L., Myles J., van der Burg M.E.L., Kerr I., Vermorken J.B., Buser K., Colombo N., Bacon M., Santabarbara P., Onetto N., Winograd B., Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer high-dose versus low-dose and long versus short infusion . J Clin Oncol. 12:1994;2654-2666.
16. Micha J.P., Rettenmaier M.A., Dillman R., Fraser P., Birk C., Brown J.V. Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol. 69:1998;122-124.
17. Bookman M.A., Kloth D.D., Kover P.E., Smolinski S., Ozols R.F. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 8:1997;611-614.
18. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol. 15:1997;3517.
19. Speyer J.L., Beller U., Colombo N., Sorich J., Wernz J.C., Hochster H., Green M., Porges R., Muggia F.M., Canetta R., Beckman E.M. Intraperitoneal carboplatin favorable results in women with minimal residual ovarian cancer after cisplatin therapy . J Clin Oncol. 8:1990;1335-1341.
20. Malmstrom H., Simonsen E., Westberg R. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol. 52:1994;20-25.
21. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B., Adelson M.D., Hoskins W.J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
22. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group . J Clin Oncol. 19:2001;1001-1007.
23. Armstrong D.K., Bundy B.N., Baergen R., Lele S.B., Copeland L.J., Walker J., Burger R. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC) a Gynecologic Oncology Group trial (GOG 172) . Proc Am Soc Clin Oncol. 21:2002;201a.
24. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer the ICON4/AGO-OVAR-2.2 trial . Lancet. 361:2003;2099-2106.